pd-0325901 and Leukemia

pd-0325901 has been researched along with Leukemia* in 1 studies

Other Studies

1 other study(ies) available for pd-0325901 and Leukemia

Article	Year
KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers. Trends in molecular medicine, 2017, Volume: 23, Issue:5 The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable. Topics: Allelic Imbalance; Benzamides; Diphenylamine; Gene Dosage; Humans; Leukemia; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Models, Theoretical; Proto-Oncogene Proteins p21(ras)	2017

Article

Year

KRAS Allelic Imbalance: Strengths and Weaknesses in Numbers.

Trends in molecular medicine, 2017, Volume: 23, Issue:5

The identification of therapeutic vulnerabilities in mutant KRAS tumors has proven difficult to achieve. Burgess and colleagues recently reported in Cell that mutant/wild-type Kras allelic dosage determines clonal fitness and MEK inhibitor sensitivity in a leukemia model, demonstrating that KRAS allelic imbalance is likely an important and overlooked variable.

Topics: Allelic Imbalance; Benzamides; Diphenylamine; Gene Dosage; Humans; Leukemia; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Models, Theoretical; Proto-Oncogene Proteins p21(ras)

2017